Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFR beta

Download
Author
Vella, LJ; Behren, A; Coleman, B; Greening, DW; Hill, AF; Cebon, JDate
2017-11-01Source Title
NeoplasiaPublisher
ELSEVIER SCIENCE INCAffiliation
Florey Department of Neuroscience and Mental HealthMedicine and Radiology
Biochemistry and Molecular Biology
Metadata
Show full item recordDocument Type
Journal ArticleCitations
Vella, L. J., Behren, A., Coleman, B., Greening, D. W., Hill, A. F. & Cebon, J. (2017). Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFR beta. NEOPLASIA, 19 (11), pp.932-940. https://doi.org/10.1016/j.neo.2017.07.002.Access Status
Open AccessAbstract
Treatment of BRAF mutant melanoma with kinase inhibitors has been associated with rapid tumor regression; however, this clinical benefit is short-lived, and most patients relapse. A number of studies suggest that the extracellular environment promotes BRAF inhibitor resistance and tumor progression. Extracellular vesicles, such as exosomes, are functional mediators in the extracellular environment. They are small vesicles known to carry a concentrated group of functional cargo and serve as intercellular communicators not only locally but also systemically. Increasingly, it is reported that extracellular vesicles facilitate the development of drug resistance in cancer; however, their role in BRAF inhibitor resistance in melanoma is unclear. Here we investigated if extracellular vesicles from BRAF inhibitor-resistant melanoma could influence drug sensitivity in recipient melanoma cells. We demonstrate that the resistance driver, PDGFRβ, can be transferred to recipient melanoma cells via extracellular vesicles, resulting in a dose-dependent activation of PI3K/AKT signaling and escape from MAPK pathway BRAF inhibition. These data suggest that the BRAF inhibitor-sensitive phenotype of metastatic melanoma can be altered by delivery of PDGFRβ by extracellular vesicles derived from neighboring drug-resistant melanoma cells.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References